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Introduction
In patients undergoing heart valve surgery
(HVS), the importance of achieving an anticoagula-
tion balance which prevents both adverse throm-
boembolic and hemorrhagic complications is well
recognized. Despite advances in reducing thrombo-
genicity of newer generation valves and the avail-
ability of safer anticoagulation regimens, throm-
boembolism and anticoagulant-related bleeding still
account for up to 75% of all complications within
six months after HVS [1]. In the long-term, poor an-
ticoagulation control with high variability of the in-
ternational normalized ratio (INR) is the strongest
independent predictor of reduced survival [2], and a
cumulative increase in the risk of adverse events is
generally observed during lifelong treatments for
mechanical valves.
In Italy more than 50,000 cardiac interventions
are currently performed every year, 40% of which
require valve implantation. Based on the First Data-
base Report [3] of the Italian Society for Cardiac
Surgery, mechanical HVS per se might account for
over 12,000 per year new initiations of lifelong an-
ticoagulation therapies nationwide. While recom-
mendations for long-term anticoagulation after HVS
have been extensively formulated, little evidence
exists for the optimal management of anticoagula-
tion in the early postoperative period. As such, a
clear comparison of the most common strategies
currently adopted (i.e., oral warfarin starting on
postoperative day one (i) without the use of heparin;
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In patients undergoing heart valve surgery (HVS) who
require warfarin therapy, the maintenance of low variabili-
ty in the level of anticoagulation early after operation is gen-
erally difficult. Aim of this study was to evaluate the time in
therapeutic range (TTR) in HVS patients receiving oral an-
ticoagulation therapy (OAT) during phase I-II of cardiac re-
habilitation (CR), and, secondly, to identify clinical vari-
ables associated with inadequate anticoagulation.
Methods: Observational study of consecutive in-hospi-
tal patients directly tracked from a cardiac surgery unit to a
CR facility. OAT was monitored both in terms of adminis-
tered warfarin doses and resulted INR values, from day 1 to
day 15 after operation. Clinical variables were tested in a lo-
gistic regression model for the prediction of inadequate an-
ticoagulation, defined as the presence of nontherapeutic
INRs for ≥5 days between day 8 and 15.
Results: Eighty-one patients (males 56%, age 62±19
yrs.), following valvuloplasty (37%), mechanical (17%), and
bioprosthetic (45%) valve replacement were considered. The
prescribed warfarin dosages were significantly higher from
day 1 to day 7 than from day 8 to day 15 (4.6±3.6 and 3.0±1.1
mg respectively, p< 0.001). Overall, TTR was 6±3 days, while
time with elevated and lower INRs accounted for 1.3±1.6 and
8.0±3.5 days respectively. At day 7, only 25% of patients (n=
20) showed a therapeutic INR value. Inadequate anticoagu-
lation between postoperative day 8 and 15 was displayed in
41 (51%) patients, with hypertension as the only independent
predictor (p< 0.001) at multivariate analysis. 
Conclusions: Despite intensive monitoring, half of pa-
tients have nontherapeutic INR values (mainly subthera-
peutic) in the first two weeks after HVS while on warfarin.
Giving the high risk of completing the hospitalization phase
without a stable OAT in many patients, both cardiac sur-
geons and cardiologists should not miss the opportunity to
improve patients education, and consider a direct track to
anticoagulation management services after discharge.
Keywords: anticoagulation, valve surgery, cardiac reha-
bilitation.
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(ii) with intravenous unfractionated heparin; (iii)
with low molecular weight heparin beginning in the
early hours after surgery and continuating until a
therapeutic INR has been achieved) is not actually
available [1]. With an average postoperative hospi-
talization of 10 days [3], it could be reasonably ar-
gued that HVS patients rarely display optimal and
stable levels of anticoagulation at discharge from
surgery units, due to haemodynamic and haemostat-
ic alterations induced by cardiopulmonary bypass.
Multidisciplinary cardiac rehabilitation (CR)
programmes showed clear benefits after cardiac
surgery. To date, patients undergoing HVS account
for up to one fourth of all patients referred to CR
programs (data from the 2008 Italian SurveY of car-
Diac rEhabilitation - Scientific Committee of the
Italian Society of Cardiac Rehabilitation and Pre-
vention, personal communication), and a growing
body of literature was historically devoted to the im-
provement in functional capacity as a result of exer-
cise training after operation [4]. However, since CR
should be a multidimensional intervention also de-
signed to reduce condition-related morbidity and
mortality and enhance quality of life, an adequate
management of anticoagulation may be identified as
a major core component of programs delivered.
Aim of this study was to evaluate the time in
therapeutic range (TTR) in patients after HVS re-
ceiving oral anticoagulation therapy during phase I-
II of CR, and secondly, to identify clinical variables
associated with inadequate anticoagulation.
Methods
We performed an observational study of consec-
utive HVS patients directly tracked from a cardiac
surgery unit to a CR facility. Oral anticoagulation
therapy - as managed by the attending physician,
with a starting dose of 5 mg warfarin on postopera-
tive day 1 plus weight-adjusted doses of enoxaparin
until a therapeutic INR has been achieved - was
monitored both in terms of administered warfarin
doses and resulted INR values, from day 1 to day 15
after operation. INR monitoring was performed dai-
ly until the therapeutic range had been achieved and
maintained for at least 2 consecutive days. Then, the
frequency of testing depended on the stability of
dose response, and INR variations were derived ac-
cording to the linear interpolation method with a
minimal tolerance of 0.1. The optimal intensity of
oral anticoagulation, with related INR ranges and
targets for different operations, was derived from the
seventh American College of Chest Physicians An-
ticoagulation Consensus Guidelines [5], the latest
available at the time of the study period. Clinical
variables were tested in a logistic regression model
for the prediction of inadequate anticoagulation (de-
fined as the presence of nontherapeutic INRs for ≥5
days between day 8 and 15, when an observable an-
ticoagulant effect had been reasonably achieved), if
significant differences emerged at univariate analy-
sis. During the study period, a strict survey for
thromboembolic (namely, the presence of thrombi in
the proximity of valves as identified by echocardio-
graphy, or the evidence of peripheral and coronary
embolization) and bleeding (namely, documented
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bleeding requiring transfusion, >1 cm thickness
pericardial effusion, or central nervous system hem-
orrhage accidents) complications was instituted.
Results
Eighty-one patients (males 56%, age 62±19 yrs.),
following valvuloplasty (38%), mechanical (17%),
and bioprosthetic (45%) valve replacement, and with
operational site in the mitral (37%), aortic (43%), and
multiple (20%) position, were considered. 
The prescribed warfarin dosages were signifi-
cantly higher from day 1 to day 7 than from day 8 to
day 15 after operation (4.6±3.6 and 3.0±1.1 mg re-
spectively, p< 0.001). 
The level of anticoagulation in the whole sample
from day 1 to day 15 is shown in figure 1. Overall,
TTR was 6±3 days, while time with elevated and
lower INRs accounted for 1.3±1.6 and 8.0±3.5 days
respectively. An INR of > 5.0 was detected in 5
(6%) patients. At day 7, only 25% of patients (n=
20) showed a therapeutic INR value. Inadequate an-
ticoagulation between postoperative day 8 and 15
was displayed in 41 (51%) patients, with a signifi-
cant higher prevalence of the following clinical con-
ditions (figure 2) as compared to those who did not:
hypertension (49% vs 12%, p < 0.001), hypercho-
lesterolemia (37% vs 12%, p < 0.05), chronic renal
impairment (37% vs 0%, p < 0.001), and presence of
operation in the mitral position (49% vs 25%, p <
0.05). Demographic characteristics, diabetes, adop-
tion of antiarrhythmic drugs or antibiotics, and bio-
chemistry data (with the exception of elevated liver
enzymes) did not show significant differences be-
tween the two groups. At multivariate analysis, only
hypertension (p< 0.001) predicted the development
of inadequate anticoagulation in the short-term after
HVS. During the study period, no postoperative
complications related to anticoagulation occurred.
Discussion
In this observational study focused on the early
postoperative period after HVS, we found that half of
patients had inadequate anticoagulation despite inten-
sive INR monitoring, in absence of major anticoagu-
lation-related events under strict medical supervision.
As mentioned above, an effective anticoagula-
tion strategy should be part of the early management
of patients after HVS, aimed to minimize the risk of
thromboembolic events and bleeding complications.
In patients following mitral valve replacement, the
risk of thromboembolic events is up to 21 per 100 pa-
tient years in the early postoperative period as com-
pared to 2.5 per 100 patient in the subsequent 5-year
follow-up, and a similar trend is shown after aortic
valve replacement and valvuloplasty at a less degree
of risk [6]. On the other hand, major bleeding events
may occurr in up to 3% of HVS patients immediate-
ly after the initiation of oral anticoagulants, with gas-
trointestinal and intracranial hemorrhages as those
associated with the highest morbidity and mortality
[7]. As reported by Ageno et al [8, 9], patients are
highly sensitive to warfarin during the first 5 days of
anticoagulation after HVS, and require a great num-
ber of dose adjustements. According to our data, the
maintenance of a stable dose response is a major con-
cern also during the second week after operation, and
the evenience of subtherapeutic rather than exagger-
ated anticoagulation seems to be predominant.
Unfortunately, several pathogenetic factors re-
lated to HVS patients, as far as the lack of a large
consensus on the optimal anticoagulation strategy in
the early postoperative period, contribute to reduce
the proportion of patients who receive the proven
level of effective care. Facing the development of
prosthetic or native valve thromboembolism (in case
of valve replacement or repair respectively), is a
challenge that begins immediately after surgery:
once the cardiopulmonary bypass terminates and
blood flows across the valves, platelets start to ag-
gregate and adhere on damaged perivalvular tissues
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Figure 2. - Presence of different clinical characteristics among patients with adequate and inadequate anticoagulation from day 8 to day 15 after heart
valve surgery.
Figure 1. - Levels of anticoagulation (expressed as mean±SD INR) from day 1 to day 15 after heart valve surgery (HVS).
and prosthetic surface, while the activation of coag-
ulation factors promotes clot formation. In the fol-
lowing period, other patient-related factors may fur-
ther enhance thrombogenicity, as in case of delayed
endothelization of exposed surfaces, or blood stasis
induced by postoperative atrial fibrillation, dilated
cardiac chambers, and regional wall motion abnor-
malities. To preserve the integrity of valves with the
lowest rate of bleeding, most work has been related
on the optimal intensity of oral anticoagulation in
the long-term, defined as the target INR on which
different HVS interventions should be anticoagulat-
ed. Less attention was conversely paid to the correct
strategy for rapidly achieving these INR targets,
comprehensive of the disadvantages that often
emerge in the early postoperative setting, such as the
increased risk of hemopericardium and mediastinic
bleeding, the persistence of haemostatic imbalance,
the presence of infections, and the use of antibiotic
or antiarrhytmics drugs that interfere with oral anti-
coagulants. Indeed, an integrated approach to the is-
sue of anticoagulation management after HVS
should also consider other aspects affecting the de-
cision-making process, such as the role of non-tradi-
tional risk factors for valve thromboembolism (i.e.,
smoking, hypertension, and cancer history), the dif-
ferent degree of thromboembolic risk according to
the anatomic valve position (leading to more or less
aggressive antithrombotic strategies), and the con-
comitant use of antipletelet drugs.
In this perspective, it’s not surprising that anti-
coagulation - rather than other postoperative care in-
terventions - often needs to be supervised and re-
fined over the first two weeks after HVS, thereby
claiming a patient oriented process. According to
the mission of CR in HVS patients, a coordinated in-
tervention on the matter of anticoagulation cannot
be limited to manage warfarin doses, but should al-
so include a baseline clinical assessment of the indi-
vidual thromboembolic and haemorrhagic risk, the
correction of conditions potentially interfering with
a stable anticoagulation, and the provision of struc-
tured patient education. Giving the high risk of com-
pleting the rehabilitative phase without a stable dose
response in many patients, a direct track to antico-
agulation management services after discharge
could be promoted as part of follow-up plans.
Riassunto
Il mantenimento di uno stabile livello di effica-
ce scoagulazione nei pazienti sottoposti a cardio-
chirurgia valvolare, seppure di grande importanza,
è generalmente difficile nelle prime fasi dopo l’in-
tervento. Scopo del presente lavoro è stato valuta-
re il tempo intercorso in range terapeutico di scoa-
gulazione in una popolazione di pazienti sottopo-
sta a valvuloplastica o sostituzione valvolare e di-
rettamente afferenti a una struttura di cardiologia
riabilitativa.
In questo studio osservazionale una popolazione
di 81 pazienti è stata valutata in termini di dosi di
warfarin prescritte e valori di INR raggiunti nel pe-
riodo intercorrente tra il 1° e il 15° giorno postope-
ratorio, inserendo in un modello di analisi multiva-
riata le comuni variabili cliniche potenzialmente
predittrici di inadeguata scoagulazione (quest’ulti-
ma definita come la presenza di un INR non tera-
peutico per ≥5 giorni tra la giornata 8 e 15, allor-
quando uno stabile livello di scoagulazione dovreb-
be essere concretamente raggiunto).
Risultati: Nei pazienti considerati (37% in esiti
di valvuloplastica, 17% di sostituzione valvolare
meccanica e 45% di sostituzione valvolare con pro-
tesi biologica), i dosaggi prescritti di warfarin sono
stati significativamente maggiori nella prima rispet-
to alla seconda settimana di osservazione (4.6±3.6 e
3.0±1.1 mg rispettivamente, p< 0.001). Globalmen-
te, il TTR è stato di 6±3 giorni, con 1.3±1.6 e
8.0±3.5 giornate caratterizzate da eccessivamente
alti e bassi livelli di INR, rispettivamente. Una scoa-
gulazione inadeguata durante la seconda settimana
è stata riscontrata globalmente in 41 (51%) pazien-
ti, con la sola ipertensione arteriosa a costituire un
parametro predittivo indipendente di tale condizione.
Conclusioni: Nonostante un monitoraggio intensi-
vo dell’INR, circa metà dei pazienti dopo cardiochi-
rurgia valvolare presentano valori di INR decisamente
instabili nelle prime due settimane dopo l’intervento,
generando un rischio clinico di complicanze trom-
boemboliche ed emorragiche da non sottovalutare, so-
prattutto nel setting della riabilitazione cardiologica.
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